Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Change In Receivables : ¥0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2000. Start your Free Trial

What is Jiangsu Hengrui Pharmaceuticals Co Change In Receivables?

Jiangsu Hengrui Pharmaceuticals Co's change in receivables for the quarter that ended in Mar. 2025 was ¥0 Mil. It means Jiangsu Hengrui Pharmaceuticals Co's Accounts Receivable stayed the same from Dec. 2024 to Mar. 2025 .

Jiangsu Hengrui Pharmaceuticals Co's change in receivables for the fiscal year that ended in Dec. 2024 was ¥-376 Mil. It means Jiangsu Hengrui Pharmaceuticals Co's Accounts Receivable increased by ¥376 Mil from Dec. 2023 to Dec. 2024 .

Jiangsu Hengrui Pharmaceuticals Co's Accounts Receivable for the quarter that ended in Mar. 2025 was ¥4,830 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Jiangsu Hengrui Pharmaceuticals Co's Days Sales Outstanding for the three months ended in Mar. 2025 was 61.16.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Jiangsu Hengrui Pharmaceuticals Co's liquidation value for the three months ended in Mar. 2025 was ¥25,275 Mil.

Jiangsu Hengrui Pharmaceuticals Co Change In Receivables Historical Data

The historical data trend for Jiangsu Hengrui Pharmaceuticals Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Hengrui Pharmaceuticals Co Change In Receivables Chart

Jiangsu Hengrui Pharmaceuticals Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-3,486.39

-868.27

-2,284.57

2,035.94

-375.70

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Jiangsu Hengrui Pharmaceuticals Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Jiangsu Hengrui Pharmaceuticals Co's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	4829.567	/	7205.611	*	91
=	61.16

2. In Ben Graham's calculation of liquidation value, Jiangsu Hengrui Pharmaceuticals Co's accounts receivable are only considered to be worth 75% of book value:

Jiangsu Hengrui Pharmaceuticals Co's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	24195.824	-	3743.013	+	0.75 * 4829.567	+	0.5 * 2400.982
=	25,275

Jiangsu Hengrui Pharmaceuticals Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Jiangsu Hengrui Pharmaceuticals Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Jiangsu Hengrui Pharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jiangsu Hengrui Pharmaceuticals Co Ltd (SHSE:600276) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

01276:Hong Kong

Address

No. 38, Huanghe Road, Economic, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222047

Website

http://www.hrs.com.cn

Jiangsu Hengrui Pharmaceuticals Co Ltd is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs and anti-infection medications. It specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system.

Executives

Zhang Lian Shan	Directors, senior managers
Sun Xu Gen	senior management
Yuan Kai Hong	senior management
Zou Jian Jun	senior management
	senior management
Zhang Yue Hong	senior management
Liu Xiao Han	senior management
Zhou Yun Shu	Directors, senior managers
Liao Cheng	senior management
Wang Hong Sen	senior management
Zhou Song	senior management
Tao Wei Kang	senior management
Jiang Su Mei	senior management
Dai Hong Bin	Directors, senior managers
Sun Jie Ping	Directors, senior managers

Jiangsu Hengrui Pharmaceuticals Co Headlines

No Headlines